Great expectations for GlaxoSmithKline R&D newsflow
Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant GlaxoSmithKline (LSE: GSK) in 2013, two or three of which can be transformational. “We can easily see GSK’s share price ticking upwards of £15 even in anticipation. To that end, we have been stress testing our model following the company’s late stage pipeline portfolio review, the analysts say.
Ultimately the business has faced headwinds this year, with pricing in Europe softer than had been expected. That is not new. Nor are headwinds facing the company’s respiratory portfolio, which has lost its pricing power.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze